Clinical  ||| S:0 E:9 ||| JJ
perspective ||| S:9 E:20 ||| NN
:  ||| S:20 E:22 ||| :
biomarkers  ||| S:22 E:33 ||| FW
in  ||| S:33 E:36 ||| FW
pulmonary  ||| S:36 E:46 ||| FW
arterial  ||| S:46 E:55 ||| FW
hypertension  ||| S:55 E:68 ||| FW
Biomarkers  ||| S:68 E:79 ||| NNP
are  ||| S:79 E:83 ||| VBP
objectively  ||| S:83 E:95 ||| RB
measured  ||| S:95 E:104 ||| VBN
characteristics  ||| S:104 E:120 ||| NNS
used  ||| S:120 E:125 ||| VBN
as  ||| S:125 E:128 ||| IN
indicators  ||| S:128 E:139 ||| NNS
of  ||| S:139 E:142 ||| IN
disease  ||| S:142 E:150 ||| NN
in  ||| S:150 E:153 ||| IN
clinical  ||| S:153 E:162 ||| JJ
practice  ||| S:162 E:171 ||| NN
and  ||| S:171 E:175 ||| CC
as  ||| S:175 E:178 ||| IN
surrogate  ||| S:178 E:188 ||| JJ
endpoints  ||| S:188 E:198 ||| NN
in  ||| S:198 E:201 ||| IN
clinical  ||| S:201 E:210 ||| JJ
trials ||| S:210 E:216 ||| NNS
.  ||| S:216 E:218 ||| .
The  ||| S:218 E:222 ||| DT
six-minute  ||| S:222 E:233 ||| JJ
walk  ||| S:233 E:238 ||| NN
test  ||| S:238 E:243 ||| NN
has  ||| S:243 E:247 ||| VBZ
been  ||| S:247 E:252 ||| VBN
widely  ||| S:252 E:259 ||| RB
used  ||| S:259 E:264 ||| VBN
as  ||| S:264 E:267 ||| IN
a  ||| S:267 E:269 ||| DT
trial  ||| S:269 E:275 ||| NN
endpoint  ||| S:275 E:284 ||| NN
in  ||| S:284 E:287 ||| IN
pulmonary  ||| S:287 E:297 ||| FW
arterial  ||| S:297 E:306 ||| FW
hypertension  ||| S:306 E:319 ||| FW
( ||| S:319 E:320 ||| -LRB-
PAH ||| S:320 E:323 ||| NNP
)  ||| S:323 E:325 ||| -RRB-
to  ||| S:325 E:328 ||| TO
gain  ||| S:328 E:333 ||| VB
approval  ||| S:333 E:342 ||| NN
for  ||| S:342 E:346 ||| IN
targeted  ||| S:346 E:355 ||| JJ
therapies ||| S:355 E:364 ||| NNS
.  ||| S:364 E:366 ||| .
Other  ||| S:366 E:372 ||| JJ
biomarkers  ||| S:372 E:383 ||| NNS
have  ||| S:383 E:388 ||| VBP
been  ||| S:388 E:393 ||| VBN
studied  ||| S:393 E:401 ||| VBN
to  ||| S:401 E:404 ||| TO
overcome  ||| S:404 E:413 ||| VB
certain  ||| S:413 E:421 ||| JJ
limitations  ||| S:421 E:433 ||| NNS
of  ||| S:433 E:436 ||| IN
the  ||| S:436 E:440 ||| DT
walk  ||| S:440 E:445 ||| JJ
test ||| S:445 E:449 ||| NN
.  ||| S:449 E:451 ||| .
Potential  ||| S:451 E:461 ||| JJ
clinical  ||| S:461 E:470 ||| JJ
applications  ||| S:470 E:483 ||| NNS
for  ||| S:483 E:487 ||| IN
biomarkers  ||| S:487 E:498 ||| NN
in  ||| S:498 E:501 ||| IN
PAH  ||| S:501 E:505 ||| NNP
include  ||| S:505 E:513 ||| VBP
screening ||| S:513 E:522 ||| VBG
,  ||| S:522 E:524 ||| ,
determination  ||| S:524 E:538 ||| NN
of  ||| S:538 E:541 ||| IN
prognosis ||| S:541 E:550 ||| NN
,  ||| S:550 E:552 ||| ,
and  ||| S:552 E:556 ||| CC
monitoring  ||| S:556 E:567 ||| VBG
response  ||| S:567 E:576 ||| NN
to  ||| S:576 E:579 ||| TO
therapy ||| S:579 E:586 ||| NN
.  ||| S:586 E:588 ||| .
Measurement  ||| S:588 E:600 ||| NN
of  ||| S:600 E:603 ||| IN
the  ||| S:603 E:607 ||| DT
B-type  ||| S:607 E:614 ||| JJ
natriuretic  ||| S:614 E:626 ||| JJ
peptides  ||| S:626 E:635 ||| NN
is  ||| S:635 E:638 ||| VBZ
currently  ||| S:638 E:648 ||| RB
recommended  ||| S:648 E:660 ||| VBN
by  ||| S:660 E:663 ||| IN
guidelines ||| S:663 E:673 ||| NNS
,  ||| S:673 E:675 ||| ,
despite  ||| S:675 E:683 ||| IN
a  ||| S:683 E:685 ||| DT
lack  ||| S:685 E:690 ||| NN
of  ||| S:690 E:693 ||| IN
appropriate  ||| S:693 E:705 ||| JJ
validation  ||| S:705 E:716 ||| NN
in  ||| S:716 E:719 ||| IN
the  ||| S:719 E:723 ||| DT
PAH  ||| S:723 E:727 ||| NNP
population ||| S:727 E:737 ||| NN
.  ||| S:737 E:739 ||| .
Novel  ||| S:739 E:745 ||| NN
biomarkers  ||| S:745 E:756 ||| VBZ
based  ||| S:756 E:762 ||| VBN
on  ||| S:762 E:765 ||| IN
recently  ||| S:765 E:774 ||| RB
discovered  ||| S:774 E:785 ||| VBN
pathobiologic  ||| S:785 E:799 ||| JJ
pathways  ||| S:799 E:808 ||| NNS
have  ||| S:808 E:813 ||| VBP
been  ||| S:813 E:818 ||| VBN
identified ||| S:818 E:828 ||| VBN
,  ||| S:828 E:830 ||| ,
like  ||| S:830 E:835 ||| IN
CXC  ||| S:835 E:839 ||| NNP
chemokine  ||| S:839 E:849 ||| VBD
ligand  ||| S:849 E:856 ||| CD
10 ||| S:856 E:858 ||| CD
,  ||| S:858 E:860 ||| ,
C-reactive  ||| S:860 E:871 ||| JJ
protein ||| S:871 E:878 ||| NN
,  ||| S:878 E:880 ||| ,
high-density  ||| S:880 E:893 ||| JJ
lipoprotein  ||| S:893 E:905 ||| JJ
cholesterol  ||| S:905 E:917 ||| NN
and  ||| S:917 E:921 ||| CC
growth-differentiation  ||| S:921 E:944 ||| JJ
factor-15 ||| S:944 E:953 ||| NN
.  ||| S:953 E:955 ||| .
Rigorous  ||| S:955 E:964 ||| JJ
statistical ||| S:964 E:975 ||| JJ
,  ||| S:975 E:977 ||| ,
biologic  ||| S:977 E:986 ||| NN
and  ||| S:986 E:990 ||| CC
clinical  ||| S:990 E:999 ||| JJ
validation  ||| S:999 E:1010 ||| NN
should  ||| S:1010 E:1017 ||| MD
be  ||| S:1017 E:1020 ||| VB
necessary  ||| S:1020 E:1030 ||| JJ
before  ||| S:1030 E:1037 ||| IN
any  ||| S:1037 E:1041 ||| DT
biomarker  ||| S:1041 E:1051 ||| NN
can  ||| S:1051 E:1055 ||| MD
be  ||| S:1055 E:1058 ||| VB
endorsed  ||| S:1058 E:1067 ||| VBN
for  ||| S:1067 E:1071 ||| IN
widespread  ||| S:1071 E:1082 ||| JJ
clinical  ||| S:1082 E:1091 ||| JJ
use ||| S:1091 E:1094 ||| NN
.  ||| S:1094 E:1096 ||| .
